one, global**Current status of sexual antibody drugs
1.Market size
Sexual antibodies are used in a variety of diseases. Since 1986, the first antibodies have entered the clinic, and so far, the FDA has approved nearly 100 first-class antibody drugs, which have become an important part of modern biomedicine, accounting for about 40% of the total biologics market. In recent years, the sexual antibody market has experienced sexual growth as new drugs have been approved for various human diseases, including cancer, autoimmune, metabolic, and infectious diseases. According to the data, from 2018 to 2022, the global first-class antibody drug market will increase from US$147.3 billion to US$230 billion, with a compound annual growth rate of 118%。
Data**: Guanyan Report Network.
Data**: Guanyan Report Network.
2.Market structure
*Antibody drugs are mainly divided into three categories: monoclonal antibody (MAB), bovine serum albumin (BSAB), and antibody drug conjugate (ADC). Monoclonal antibodies are widely used in cancer** and autoimmune diseases**, and are the mainstream** antibody drugs, accounting for nearly 95% in 2022. Antibody-drug conjugates accounted for only 34%, but in recent years, it has achieved remarkable curative effects on cancer**, which has attracted worldwide attention and has broad development prospects. Bovine serum protein is used to treat cerebral insufficiency, venous circulation disorders, cerebral ischemia, etc., accounting for 23%。
Data**: Guanyan Report Network.
II. II. IIThe status quo of China's most advanced antibody drugs
1.Market size andStructure
From the perspective of the domestic market, as early as the early eighties of the 20th century, Chinese scientists successfully carried out the development of monoclonal antibodies using hybridoma technology, and a large number of murine monoclonal antibodies against various antigens have been obtained so far. In 1987, the biotechnology field of the "863" Program took antibody-directed drugs as a special topic, and carried out research on antibody-directed drugs for liver cancer, lung cancer, gastric cancer, and leukemia. After more than ten years of efforts, the role of isotope-antibody, drug-antibody and toxin-antibody with murine antibody as the carrier has been evaluated in the laboratory and animal models, and gradually moved from the laboratory to the clinic. As the development of the biopharmaceutical industry enters an upward period, the first antibody drugs have accelerated into the commercialization stage. From 2018 to 2022, the market size of China's first-class antibody drugs increased from 16 billion yuan to 75.7 billion yuan, with a compound annual growth rate of 475%。Among them, MAB accounts for more than 95%.
Data**: Guanyan Report Network.
2.industryBottlenecks
While China's antibody production industry is booming, it is also facing great challenges. It is still in the stage of catching up on innovation and the transformation of cutting-edge scientific and technological achievementsThe varieties under development are mainly biosimilars, and there is a lack of original innovationThe level of antibody production, purification process, quality control and industrialization scale still lags behind the international levelKey equipment, raw materials and reagents such as bioreactors, purification systems, and scientific instruments are also dependent on imports. In the long run, there is still a lot of room for development of China's first-class antibody drugs.
Source**: Observation and Research Report Network (ZLJ).
Note: The above information is for reference only, please refer to the body of the report for details.
The "Analysis of the Development Trend and Investment Prospect of China's Antibody Drug Industry (2023-2030)" released by Guanyan Report Network covers the latest industry data, market hotspots, policy planning, competitive intelligence, market prospects, investment strategies, etc. It is supplemented by a large number of intuitive charts to help enterprises in the industry accurately grasp the development trend of the industry, market trends, and correctly formulate corporate competitive strategies and investment strategies. Based on authoritative data released by the National Bureau of Statistics, the General Administration of Customs and the State Information Center, this report combines the environment in which the industry is located, and conducts market research and analysis from multiple perspectives such as theory to practice, from macro to micro.
The industry report is one of the important decision-making bases for enterprises, relevant investment companies and first-class departments in the industry to accurately grasp the development trend of the industry, gain insight into the industry competition pattern, avoid business and investment risks, and formulate correct competition and investment strategy decisions. This report is an indispensable and important tool for a comprehensive understanding of the industry and for investing in the industry. Over the years, Guanyan has provided professional industry analysis reports for tens of thousands of enterprises, consulting institutions, financial institutions, industry associations, individual investors, etc., and its customers include Huawei, PetroChina, China Telecom, China Construction, HP, Disney and other leading enterprises at home and abroad, and have been widely recognized by customers.
Outline of the Table of Contents
Chapter 1 2019-2023Overview of the development of China's leading antibody drug industry
Section 1 **Overview of the development of the sexual antibody drug industry.
1. Relevant definitions of the antibody drug industry.
2. Analysis of the characteristics of ** antibody drugs.
3. Introduction to the basic situation of the antibody drug industry.
Fourth, the business model of the antibody drug industry.
1. Production mode.
2. Procurement mode.
3. Sales and service model.
5. Analysis of the main demand of the antibody drug industry
Section 2 Life Cycle Analysis of China's Highest Antibody Drug Industry.
1. Overview of the life cycle theory of the antibody drug industry.
2. Life cycle analysis of the antibody drug industry.
Section 3 Analysis of Economic Indicators of Antibody Drug Industry.
1. Profitability analysis of the antibody drug industry.
2. Analysis of the economic cycle of the antibody drug industry.
3. Analysis of the improvement space of the added value of the antibody drug industry.
Chapter 2 2019-2023Analysis of the development status of the global first-class antibody drug industry
Section 1 Review of the development process of the world's leading antibody drug industry.
Section 2 Market size and regional distribution of the global first-class antibody drug industry.
Section 3 Regional Market Analysis of Asia's Leading Antibody Drug Industry.
1. Analysis of the market status of Asia's leading antibody drug industry.
2. Analysis of the market size and market demand of Asia's leading antibody drug industry.
3. Analysis of the market prospect of Asia's leading antibody drug industry.
Section 4 Regional Market Analysis of North America's Antibody Drug Industry.
1. Analysis of the market status of the first-class antibody drug industry in North America.
2. Analysis of the market size and market demand of the North American antibody drug industry.
3. Analysis of the market prospect of the North American antibody drug industry.
Section 5 Regional Market Analysis of Europe's Antibody Drug Industry.
1. Analysis of the market status of the European first-class antibody drug industry.
2. Analysis of the market size and market demand of the European first-class antibody drug industry.
3. Analysis of the market prospect of the European first-class antibody drug industry.
Section 6 Distribution trend of the world's **sex antibody drug industry from 2023 to 2030**.
Section 7 Market size of the global antibody drug industry from 2023 to 2030.
Chapter IIIAnalysis of the industrial development environment of China's first-class antibody drug industry
Section 1 Analysis of China's Macroeconomic Environment.
Section 2 Analysis of the impact of China's macroeconomic environment on the first-class antibody drug industry.
Section 3 Analysis of the policy environment of China's leading antibody drug industry.
1. The current situation of the industry regulatory system.
Second, the main policies and regulations of the industry.
3. Main industry standards.
Section 4 Analysis of the impact of the policy environment on the first-class antibody drug industry.
Section 5 Analysis of the industrial and social environment of China's first-class antibody drug industry
Chapter IVThe operation of China's first-class antibody drug industry
Section 1 Introduction to the development of China's first-class antibody drug industry.
1. Review of the development process of the industry.
2. Analysis of industry innovation.
3. Analysis of the development characteristics of the industry.
Section 2 Analysis of the market size of China's first-class antibody drug industry.
1. Factors affecting the market size of China's first-class antibody drug industry.
2. The market size of China's first-class antibody drug industry.
3. Analysis of the market size of China's first-class antibody drug industry.
Section 3 Analysis of China's ** Sex Antibody Drug Industry**.
1. The scale of China's first-class antibody drug industry.
Second, the characteristics of China's first-class antibody drug industry.
Section 4 Analysis of the demand for China's leading antibody drug industry.
1. The demand scale of China's first-class antibody drug industry.
2. Characteristics of the demand of China's first-class antibody drug industry.
Section 5 Analysis of the balance of supply and demand in China's first-class antibody drug industry.
Chapter 5Analysis of the industrial chain and market segments of China's first-class antibody drug industry
Section 1 Overview of the industrial chain of China's first-class antibody drug industry.
1. Introduction to the principle of the industrial chain model.
Second, the operation mechanism of the industrial chain.
3. **Sexual antibody drug industry chain**.
Section 2 Analysis of the industrial chain of China's first-class antibody drug industry.
First, the development status of upstream industries.
2. Analysis of the impact of the upstream industry on the first-class antibody drug industry.
Third, the development status of downstream industries.
4. Analysis of the impact of downstream industries on the first-class antibody drug industry.
Section 3 Analysis of the market segments of China's leading antibody drug industry.
First, market segment one.
Second, market segment two.
Chapter 6 2019-2023Market competition analysis of China's leading antibody drug industry
Section 1 Analysis of the current situation of competition in China's first-class antibody drug industry.
1. Analysis of the competitive landscape of China's first-class antibody drug industry.
Second, the main products of China's first-class antibody drug industry
Section 2 Analysis of the concentration of China's first-class antibody drug industry.
1. Analysis of the influencing factors of market concentration in China's first-class antibody drug industry.
2. Analysis of the market concentration of China's first-class antibody drug industry.
Section 3 Analysis of the Competition Characteristics of China's Antibody Drug Industry.
1. Characteristics of regional distribution of enterprises.
Second, the distribution characteristics of enterprise scale.
3. Characteristics of the distribution of enterprise ownership.
Chapter 7 2019-2023Model analysis of China's leading antibody drug industry
Section 1 Analysis of the Competitive Structure of China's Antibody Drug Industry (Porter's Five Forces Model).
1. The principle of Porter's Five Forces Model.
Second, the bargaining power.
3. Bargaining power of buyers.
Fourth, the threat of new entrants.
5. Threat of substitutes.
Sixth, the degree of competition in the same industry.
7. Conclusion of Porter's Five Forces Model.
Section 2 SWOT analysis of China's leading antibody drug industry.
1. Overview of the SOWT model.
Second, the analysis of industry advantages.
Third, the disadvantages of the industry.
Fourth, industry opportunities.
5. Industry threats.
6. SWOT analysis conclusion of China's leading antibody drug industry.
Section 3 Analysis of the Competitive Environment (PEST) of China's Antibody Drug Industry
1. Overview of the PEST model.
Second, policy factors.
3. Economic factors.
Fourth, social factors.
Fifth, technical factors.
6. Conclusions of PEST model analysis.
Chapter 8 2019-2023Analysis of the demand characteristics and dynamics of China's leading antibody drug industry
Section 1 Market dynamics of China's first-class antibody drug industry.
Section 2 Analysis of the characteristics of the consumer market of China's first-class antibody drug industry.
1. Demand preference.
2. Preferences.
3. Brand preference.
4. Other preferences.
Section 3 Analysis of the cost structure of the antibody drug industry.
Section 4 Analysis of Influencing Factors of Sexual Antibody Drug Industry.
1. Supply and demand factors.
Second, the cost factor.
3. Other factors.
Section 5 Analysis of the current situation of China's ** sex antibody drug industry.
Section 6 Average Trend of China's Sexual Antibody Drug Industry.
1. Analysis of the average trend of China's first-class antibody drug industry.
2. Factors influencing the average change of China's first-class antibody drug industry.
CHAPTER IXMonitoring of the operation data of the industry to which China's first-class antibody drug industry belongs
Section 1 Analysis of the overall scale of China's first-class antibody drug industry.
1. Analysis of the number and structure of enterprises.
2. Analysis of the scale of industry assets.
Section 2 Analysis of the production, sales and cost of China's leading antibody drug industry.
1. Current assets.
Second, sales revenue analysis.
3. Liability analysis.
Fourth, the analysis of profit scale.
5. Analysis of output value.
Section 3 Analysis of the financial indicators of China's leading antibody drug industry.
1. Industry profitability analysis.
2. Analysis of the solvency of the industry.
3. Analysis of industry operating capabilities.
Fourth, the analysis of industry development capabilities.
Chapter 10 2019-2023Analysis of the regional market status of China's leading antibody drug industry
Section 1 Analysis of the regional market size of China's first-class antibody drug industry.
1. Factors affecting the regional market distribution of the ** antibody drug industry.
2. Regional market distribution of China's first-class antibody drug industry.
Section 2 Market Analysis of the Antibody Drug Industry in East China.
1. Overview of East China.
2. Analysis of the economic environment in East China.
3. Market analysis of the first-class antibody drug industry in East China.
1) The market size of the first antibody drug industry in East China.
2) The market status of the first-class antibody drug industry in South China.
3) The market size of the antibody drug industry in East China.
Section 3 Market Analysis in Central China.
1. Overview of Central China.
2. Analysis of the economic environment in central China.
3. Market analysis of the leading antibody drug industry in Central China.
1) The market size of the first antibody drug industry in Central China.
2) The market status of the first-class antibody drug industry in Central China.
3) The market size of the antibody drug industry in Central China.
Section 4 Market Analysis in South China.
1. Overview of South China.
2. Analysis of the economic environment in South China.
3. Market analysis of the first-class antibody drug industry in South China.
1) The market size of the first antibody drug industry in South China.
2) The market status of the first-class antibody drug industry in South China.
3) The market size of the antibody drug industry in South China.
Section 5 Market Analysis of the Antibody Drug Industry in North China.
1. Overview of North China.
2. Analysis of the economic environment in North China.
3. Market analysis of the first-class antibody drug industry in North China.
1) The market size of the first antibody drug industry in North China.
2) The market status of the first-class antibody drug industry in North China.
3) The market size of the antibody drug industry in North China.
Section 6 Market Analysis in Northeast China.
1. Overview of the Northeast region.
2. Analysis of the economic environment in Northeast China.
3. Market analysis of the first-class antibody drug industry in Northeast China.
1) The market size of the first-class antibody drug industry in Northeast China.
2) The market status of the first-class antibody drug industry in Northeast China.
3) The market size of the antibody drug industry in Northeast China.
Section 7 Market Analysis in Southwest China.
1. Overview of the Southwest Region.
2. Analysis of the economic environment in southwest China.
3. Market analysis of the first-class antibody drug industry in southwest China.
1) The market size of the first antibody drug industry in southwest China.
2) The market status of the first-class antibody drug industry in Southwest China.
3) The market size of the antibody drug industry in southwest China.
Section 8 Market Analysis in Northwest China.
1. Overview of the Northwest Territories.
2. Analysis of the economic environment in Northwest China.
3. Market analysis of the first-class antibody drug industry in Northwest China.
1) The market size of the first sex antibody drug industry in Northwest China.
2) The market status of the first-class antibody drug industry in Northwest China.
3) The market size of the antibody drug industry in Northwest China.
Chapter XI**Analysis of companies in the antibody drug industry (subject to adjustment as data is updated).
Section 1 Enterprises.
First, the company profile.
Second, the main products.
3. Operation.
1. Main economic indicators.
2. Analysis of corporate profitability.
3. Analysis of corporate solvency.
4. Analysis of enterprise operation capabilities.
5. Analysis of enterprise growth ability.
Fourth, the company's advantages analysis.
Section 2: Enterprises.
First, the company profile.
Second, the main products.
3. Operation.
Fourth, the company's advantages and disadvantages analysis.
Section 3: Enterprises.
First, the company profile.
Second, the main products.
3. Operation.
Fourth, the company's advantages analysis.
Section 4 Enterprises.
First, the company profile.
Second, the main products.
3. Operation.
Fourth, the company's advantages analysis.
Section 5 Enterprises.
First, the company profile.
Second, the main products.
3. Operation.
Fourth, the company's advantages analysis.
Section 6 Enterprises.
First, the company profile.
Second, the main products.
3. Operation.
Fourth, the company's advantages analysis.
Section 7: Enterprises.
First, the company profile.
Second, the main products.
3. Operation.
Fourth, the company's advantages analysis.
Section 8 Enterprises.
First, the company profile.
Second, the main products.
3. Operation.
Fourth, the company's advantages analysis.
Section 9 Enterprises.
First, the company profile.
Second, the main products.
3. Operation.
Fourth, the company's advantages analysis.
Section 10 Enterprises.
First, the company profile.
Second, the main products.
3. Operation.
Fourth, the company's advantages analysis.
Chapter 12 2023-2030Analysis of the development prospect of China's ** antibody drug industry
Section 1 Analysis of the future development prospects of China's first-class antibody drug industry.
1. Analysis of the domestic investment environment of the first antibody drug industry.
2. Analysis of market opportunities in China's leading antibody drug industry.
3. The growth rate of investment in China's ** antibody drug industry**.
Section 2 Future Development Trend of China's Sexual Antibody Drug Industry.
Section 3 Scale Development of China's Sexual Antibody Drug Industry.
1. The market size of China's **sex antibody drug industry**.
Second, the market size growth rate of China's ** antibody drug industry.
3. The output value scale of China's ** antibody drug industry.
Fourth, the growth rate of the output value of China's ** antibody drug industry.
5. Supply and demand of China's ** antibody drug industry**.
Section 4 Profit trend of China's **sex antibody drug industry**.
Chapter 13 2023-2030Analysis of entry barriers and investment risks in China's first-class antibody drug industry
Section 1 Analysis of the entry barriers of China's first-class antibody drug industry.
1. Analysis of financial barriers in the antibody drug industry.
2. Analysis of technical barriers in the antibody drug industry.
3. Analysis of talent barriers in the antibody drug industry.
Fourth, the analysis of brand barriers in the first-class antibody drug industry.
5. Analysis of other barriers in the antibody drug industry.
Section 2 Risk Analysis of the Antibody Drug Industry.
1. Macro environmental risks of the antibody drug industry.
2. Technical risks in the antibody drug industry.
3. Competition risks in the antibody drug industry.
Fourth, other risks in the antibody drug industry.
Section 3 Problems in China's first-class antibody drug industry.
Section 4 Analysis of the Problem Solving Strategy of China's Antibody Drug Industry.
Chapter 14 2023-2030Research conclusions and investment suggestions of China's first-class antibody drug industry
Section 1 A review of the research on China's leading antibody drug industry.
First, the investment value of the industry.
2. Industry risk assessment.
Section 2 Analysis of the entry strategy of China's first-class antibody drug industry.
First, the target customer group of the industry.
Second, the selection of market segments.
Third, the choice of regional market.
Section 3 Analysis of Marketing Strategies of the Sexual Antibody Drug Industry.
1. Product strategy of the first antibody drug industry.
Second, the pricing strategy of the first antibody drug industry.
3. Channel strategy of the antibody drug industry.
Fourth, the first strategy of the antibody drug industry.
Section 4 Investment Advice from Analysts.